Abbott Makes First Xience Submission To FDA As Guidant Biz Boosts Sales
This article was originally published in The Gray Sheet
Executive Summary
Abbott kicked off the premarket approval submission process July 19 for the Xience everolimus-eluting coronary stent, taking a step closer to capitalizing on its recent acquisition of Guidant's vascular business
You may also be interested in...
Abbott Vascular Prospects Aid 23% Stock Gain In 2006 – Index Up 5.7%
Abbott's and Johnson & Johnson's guidance to the device industry in 2006 was that diversification is key and some acquisitions are too good to pass up
Abbott Vascular Prospects Aid 23% Stock Gain In 2006 – Index Up 5.7%
Abbott's and Johnson & Johnson's guidance to the device industry in 2006 was that diversification is key and some acquisitions are too good to pass up
J&J Gains Next-Gen CoStar Stent Through $1.4 Bil. Conor Purchase
Johnson & Johnson hopes that its $1.4 bil. purchase of next-generation drug-eluting stent developer Conor Medsystems will help it retain top-tier market share as a flurry of new competitors joins the market